bluebird bio, Inc. (NASDAQ:BLUE) Receives Average Rating of “Hold” from Analysts

Shares of bluebird bio, Inc. (NASDAQ:BLUE) have received an average recommendation of “Hold” from the nine ratings firms that are covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $49.14.

Several research analysts have issued reports on the stock. StockNews.com assumed coverage on shares of bluebird bio in a research report on Friday, December 20th. They issued a “sell” rating on the stock. Barclays lifted their target price on bluebird bio from $2.00 to $40.00 and gave the stock an “overweight” rating in a report on Tuesday, December 31st. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $80.00 target price on shares of bluebird bio in a report on Friday, November 15th. Bank of America cut bluebird bio from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $60.00 to $10.00 in a research note on Friday, November 15th. Finally, JPMorgan Chase & Co. lowered shares of bluebird bio from a “neutral” rating to an “underweight” rating in a research note on Friday, November 15th.

Hedge Funds Weigh In On bluebird bio

Institutional investors and hedge funds have recently bought and sold shares of the business. Verition Fund Management LLC acquired a new stake in shares of bluebird bio during the third quarter worth approximately $42,000. SG Americas Securities LLC lifted its position in bluebird bio by 152.4% in the 3rd quarter. SG Americas Securities LLC now owns 122,855 shares of the biotechnology company’s stock worth $64,000 after buying an additional 74,185 shares in the last quarter. Captrust Financial Advisors boosted its stake in shares of bluebird bio by 48.2% during the 3rd quarter. Captrust Financial Advisors now owns 237,648 shares of the biotechnology company’s stock valued at $123,000 after buying an additional 77,293 shares during the period. Barclays PLC grew its holdings in shares of bluebird bio by 273.7% during the 3rd quarter. Barclays PLC now owns 252,062 shares of the biotechnology company’s stock valued at $130,000 after acquiring an additional 184,605 shares in the last quarter. Finally, Rhumbline Advisers grew its holdings in shares of bluebird bio by 25.4% during the 2nd quarter. Rhumbline Advisers now owns 292,436 shares of the biotechnology company’s stock valued at $288,000 after acquiring an additional 59,219 shares in the last quarter. Hedge funds and other institutional investors own 87.43% of the company’s stock.

bluebird bio Stock Performance

Shares of BLUE opened at $8.35 on Friday. The company has a debt-to-equity ratio of 0.37, a current ratio of 0.51 and a quick ratio of 0.33. The firm’s 50 day moving average is $8.12 and its 200-day moving average is $12.18. bluebird bio has a 12-month low of $5.80 and a 12-month high of $38.40. The stock has a market capitalization of $81.16 million, a P/E ratio of -0.22 and a beta of 0.68.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.